title: Bladder cancer: inter-relationships between chemotherapy and radiotherapy.
abstract: There has been increasing interest in the role of chemotherapy as primary treatments for patients with urothelial cancer and because of the poor prognosis of locally advanced tumours with conventional treatment, trials have been initiated comparing radiotherapy with chemotherapy as primary therapies. In this context it is important to assess the relationship between the responses to chemotherapy and radiotherapy, and this we have examined in 64 patients treated with MVMJ (methotrexate, vinblastine, mitozantrone and carboplatin). Either a complete or a partial response was found in 29 of the 64 patients, 15 had stable disease and 13 had progression of disease. Seven patients died within the first treatment month. The survival of the responding patients ranged from 114 to 1184 days. Six of 15 patients who had had pelvic irradiation prior to chemotherapy responded to MVMJ, the maximum duration of response being more than 3 years. Twenty-two patients had radiotherapy following their chemotherapy. One of 13 patients not responding to MVMJ had a transient response to radical radiotherapy. Only 1 of 9 patients responding to chemotherapy and then relapsing responded to subsequent radical radiotherapy. Patients with metastatic disease or with recurrent disease after radiotherapy have a worthwhile chance of responding to chemotherapy and achieve durable remissions. In contrast, radiotherapy appears relatively ineffective in patients whose disease progresses or relapses after chemotherapy given as primary treatment with curative intent.
authors.affiliation: Department of Clinical Oncology, Royal Postgraduate Medical School, London.
authors.forename: J
authors.initials: J
authors.lastname: Waxman
authors.forename: C
authors.initials: C
authors.lastname: Barton
authors.forename: R
authors.initials: R
authors.lastname: Biruls
authors.forename: N
authors.initials: N
authors.lastname: James
authors.forename: M
authors.initials: M
authors.lastname: Harrison
authors.forename: H
authors.initials: H
authors.lastname: Rogers
authors.forename: D
authors.initials: D
authors.lastname: Mee
authors.forename: K
authors.initials: K
authors.lastname: Sikora
authors.forename: R
authors.initials: R
authors.lastname: Colbeck
authors.forename: P
authors.initials: P
authors.lastname: Abel
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D011878:Radiotherapy; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000628:therapy*; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D014747:Vinblastine; D016190:Carboplatin; D008942:Mitoxantrone; D008727:Methotrexate